Today, the President & CEO of OncoMed Pharma (NASDAQ: OMED), John Lewicki, sold shares of OMED for $2,323.
In addition to John Lewicki, 6 other OMED executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on OncoMed Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $6.87 million and GAAP net loss of $3.98 million. In comparison, last year the company earned revenue of $5.11 million and had a GAAP net loss of $10.69 million. Currently, OncoMed Pharma has an average volume of 50.98K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer’s growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.
